Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nyse  >  Merck & Co., Inc.    MRK

SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets 

Merck Combination Cholesterol Drug Fails to Meet Study Goals; Firm Doesn't Plan to Seek U.S. Approval

share with twitter share with LinkedIn share with facebook
share via e-mail
0
12/20/2012 | 03:17pm CEST
   By Tess Stynes 
 

Merck & Co. (>> Merck & Co., Inc.) said its doesn't plan to seek U.S. Food and Drug Administration for a combination cholesterol treatment that aims to reduce the risk of cardiovascular events after the drug failed to meet primary goals in a large long-term study.

Shares were down 2.9% at $42.40 in premarket trading.

The pharmaceutical giant said it isn't recommending that health-care providers start new patients on the treatment--Tredaptive--an extended release combination of niacin and laropiprant. The company also plans to share the study results with health regulators in countries where it also is approved under the Tredaptive or Cordaptive brands.

"While we are disappointed in these results, we thank the investigators who have conducted the study and the patients who have participated in it," said Peter S. Kim, president, Merck Research Laboratories.

The study that compared extended-release niacin and laropiprant plus statin therapy versus statin therapy included 25,673 patients in Britain, Scandinavia and China considered at risk for cardiovascular issues that were followed for a median 3.9 years.

The study found that the combination drug along with statin therapy didn't significantly further reduce the risk of a combination of cardiovascular events such as nonfatal heart attacks, strokes or coronary-related deaths compared with just statin therapy. There also was an increase in nonfatal events in the group receiving Tredaptive.

Further analysis is under way and detailed study results are expected in the first quarter.

Write to Tess Stynes at [email protected]

Subscribe to WSJ: http://online.wsj.com?mod=djnwires

Stocks mentioned in the article : Merck & Co., Inc.
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on MERCK & CO., INC.
05/23 MERCK : FDA Approves Merck’s KEYTRUDA® (pembrolizumab) for Adult and Pedia..
05/23DJMERCK : FDA OKs Merck's Keytruda to Treat Cancers With Genetic Defects -- Update
05/23DJMERCK : FDA Approves Merck's Keytruda to Treat Cancers With Genetic Defects
05/23 MERCK : Announces Third-Quarter 2017 Dividend
05/23 MERCK & CO., INC. (NYSE : MRK) ISENTRESS Receives Positive Opinion From CHMP
05/23 UK competition watchdog accuses Merck of obstructing biosimilars
05/23 MERCK : FDA Grants Priority Review to Merck’s Supplemental Biologics Licen..
05/22 MERCK : Announces Presentation of Phase 2 Results for MK-7264, an Investigationa..
05/22 MERCK : Contractor Hits 5 Million Safe Hours
05/20 MERCK : CHMP Adopts Positive Opinion For Isentress 600 Mg In EU
More news
Sector news : Pharmaceuticals - NEC
12:20p FTSE edge up helped by M&S but miners weigh
05/23DJALEXION PHARMACEUTICALS : Shakeup Continues as Four Executives Exit -- 2nd Updat..
05/23DJALEXION PHARMACEUTICALS : Shakeup Continues as Four Executives Exit -- Update
05/23DJALEXION PHARMACEUTICALS : Management Shakeup Continues as Four More Executives E..
05/23 UK competition watchdog accuses Merck of obstructing biosimilars
More sector news : Pharmaceuticals - NEC
News from SeekingAlpha
11:28a AMGEN : Comments On Romo, Biosimilars, And Repatha
08:35a Healthcare Unicorns And Where To Find Them
05/23 PFIZER VS. MERCK : 4 Reasons One Is The Superior Choice
05/23 FDA OKs Merck's Keytruda for certain solid tumors
05/23 Merck & Co's (MRK) Annual Shareholders Meeting Brokers Conference (Transcript..
Advertisement
Financials ($)
Sales 2017 39 930 M
EBIT 2017 13 655 M
Net income 2017 7 128 M
Debt 2017 942 M
Yield 2017 2,91%
P/E ratio 2017 24,85
P/E ratio 2018 18,83
EV / Sales 2017 4,45x
EV / Sales 2018 4,32x
Capitalization 176 555 M
More Financials
Chart MERCK & CO., INC.
Duration : Period :
Merck & Co., Inc. Technical Analysis Chart | MRK | US58933Y1055 | 4-Traders
Full-screen chart
Technical analysis trends MERCK & CO., INC.
Short TermMid-TermLong Term
TrendsBullishNeutralBullish
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 22
Average target price 69,3 $
Spread / Average Target 7,4%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Kenneth C. Frazier Chairman, President & Chief Executive Officer
Robert M. Davis Chief Financial Officer & Executive Vice President
Clark Golestani Chief Information Officer & Executive VP
Thomas Henry Glocer Independent Director
Rochelle B. Lazarus Independent Director
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
MERCK & CO., INC.9.65%175 160
JOHNSON & JOHNSON10.46%342 817
ROCHE HOLDING LTD.14.79%237 610
NOVARTIS AG6.28%213 719
PFIZER INC.-1.05%191 279
SANOFI14.93%124 306
More Results